Atropine for the Prevention of Myopia Progression in Children: A Report by the American Academy of Ophthalmology.
Jules Stein Eye Institute, Los Angeles, California.
Jaeb Center for Health Research, Tampa, Florida.
Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia.
Eye Surgery Associates, LLC, Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, Connecticut.
Casey Eye Institute, Oregon Health & Science University, Portland, Oregon.
Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California.
- Published Article
- Publication Date
Dec 01, 2017
Level I evidence supports the use of atropine to prevent myopic progression. Although there are reports of myopic rebound after treatment is discontinued, this seems to be minimized by using low doses (especially atropine 0.01%).
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/28669492